Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Renal leiomyosarcoma.
Beardo P, José Ledo M, Jose Luis RC. Beardo P, et al. Rare Tumors. 2013 Sep 4;5(3):e42. doi: 10.4081/rt.2013.e42. eCollection 2013. Rare Tumors. 2013. PMID: 24179654 Free PMC article.
Maintenance Therapy with 3-monthly Bacillus Calmette-Guérin for 3 Years is Not Superior to Standard Induction Therapy in High-risk Non-muscle-invasive Urothelial Bladder Carcinoma: Final Results of Randomised CUETO Study 98013.
Martínez-Piñeiro L, Portillo JA, Fernández JM, Zabala JA, Cadierno I, Moyano JL, Solsona E, Unda M, Beardo P, Rodríguez-Molina J, Chantada V, Palou J, Muntañola P, Alonso Dorrego JM, Pérez-Garcia FJ, Silva JM, Chesa N, Montesinos M, Ojea A, Madero R, Martínez-Piñeiro JA. Martínez-Piñeiro L, et al. Among authors: beardo p. Eur Urol. 2015 Aug;68(2):256-62. doi: 10.1016/j.eururo.2015.02.040. Epub 2015 Mar 18. Eur Urol. 2015. PMID: 25794457 Clinical Trial.
Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial.
Solsona E, Madero R, Chantada V, Fernandez JM, Zabala JA, Portillo JA, Alonso JM, Astobieta A, Unda M, Martinez-Piñeiro L, Rabadan M, Ojea A, Rodriguez-Molina J, Beardo P, Muntañola P, Gomez M, Montesinos M, Martinez Piñeiro JA; Members of Club Urológico Español de Tratamiento Oncológico. Solsona E, et al. Among authors: beardo p. Eur Urol. 2015 Mar;67(3):508-16. doi: 10.1016/j.eururo.2014.09.026. Epub 2014 Oct 6. Eur Urol. 2015. PMID: 25301758 Clinical Trial.
Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NIMBUS".
Grimm MO, van der Heijden AG, Colombel M, Muilwijk T, Martínez-Piñeiro L, Babjuk MM, Türkeri LN, Palou J, Patel A, Bjartell AS, Caris C, Schipper RG, Witjes WPJ; EAU Research Foundation NIMBUS Study Group. Grimm MO, et al. Eur Urol. 2020 Nov;78(5):690-698. doi: 10.1016/j.eururo.2020.04.066. Epub 2020 May 20. Eur Urol. 2020. PMID: 32446864 Clinical Trial.
Rare secondary carcinoma from bladder to testis.
Beardo P, Manasia P, Corral JM, Truan D, Alcover JB, Micali F. Beardo P, et al. Urol Int. 2002;68(3):204-5. doi: 10.1159/000048453. Urol Int. 2002. PMID: 11919471
Optimizing treatment for non muscle-invasive bladder cancer with an app.
Beardo P, Pinto R, Ayerra H, Agüera J, Armijos S, Álvarez-Ossorio JL. Beardo P, et al. Actas Urol Esp (Engl Ed). 2022 May;46(4):230-237. doi: 10.1016/j.acuroe.2021.12.010. Epub 2022 Mar 17. Actas Urol Esp (Engl Ed). 2022. PMID: 35307306 Clinical Trial. English, Spanish.
14 results